Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients

By Nikita Chaurasia  | Date: 2020-08-26

Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients

U.S.-based multinational pharmaceutical giant Merck & Co. Inc. recently announced that its anti-PD-1 therapy named as KEYTRUDA, has received approvals from Japan Pharmaceuticals as well as from Medical Devices Agency (PMDA).

As per the trusted sources, KEYTRUDA monotherapy is approved to treat patients suffering tumors that are PD-L1-positive and have radically unresectable, recurrent or advanced esophageal squamous cell carcinoma (ESCC).

It is to be noted that KEYTRUDA is an anti-PD-1 therapy that improves body’s immune system and also detects and counters tumor cells. The therapy was initially approved to be used at prescribed dosage of 400 mg every six weeks (Q6W), which is operates as an intravenous infusion over 30 minutes across all adult indications, including combination therapy and KEYTRUDA monotherapy, sources claimed.

Dr. Jonathan Cheng, Vice President of oncology clinical research, Merck Research Laboratories reportedly stated that the company is focusing on improving results for as many cancer patients as possible including those with esophageal squamous cell carcinoma, which is a major reason for cancer-related deaths in Japan.

Cheng further added that by using KEYTRUDA the adult patients will now have the provision of a dosing schedule that helps in decreasing the tumor based on how frequently they are at the clinic for treatment.

Jannie Oosthuizen, President at MSD Japan mentioned that over 90% of esophageal cancers are squamous cell carcinomas. Patients who are suffering from advanced disease face poor prognosis and have a critical requirement of better treatment options, he further claimed.

According to the reliable sources, KEYTRUDA’s approval for 400 mg for every six weeks is based on exposure-response analyses and pharmacokinetic modeling. The interim analysis was reportedly based on the pharmacokinetic modeling data, as well as on safety and efficacy data from KEYNOTE-555 which was gathered from a cohort of patients (Cohort B) who use KEYTRUDA 400 mg Q6W.

Source credits-

https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-two-new-approvals-in-japan/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Tatas in plans to acquire Bisleri in a deal worth USD 856 million

Tatas in plans to acquire Bisleri in a deal worth USD 856 million

By Nikita Chaurasia

India's fast-moving consumer goods company, Tata Consumer Products Ltd is reportedly all set to acquire drink company, Bisleri International in a deal worth USD 856 million (₹7000 crores), reported the packaged water makers chairman, Ramesh...

Ukio raises $28M to offer comfort to working professionals across Europe

Ukio raises $28M to offer comfort to working professionals across Europe

By Nikita Chaurasia

Ukio, an apartment rental agency in Barcelona, Spain, has reportedly raised $28 million (€27 million) in a Series A round of funding. Apparently, the cash injection consists of over $17.5 million (€17 million) in equity and more than $10...

Amazon’s AWS unveils 2nd infrastructure region in Hyderabad, India

Amazon’s AWS unveils 2nd infrastructure region in Hyderabad, India

By Nikita Chaurasia

IT service management company, Amazon Web Services, Inc. (AWS), has recently announced the unveiling of another leading AWS infrastructure region in India, the AWS Asia Pacific (Hyderabad) Region. Starting this week, the startups, developers, ente...

Beijing reports increase in COVID-19 cases after first death in six months

Beijing reports increase in COVID-19 cases after first death in six months

By Nikita Chaurasia

World's most populous country, China has recently reported the fatalities of three people in Beijing as the first fatalities from coronavirus in the last six months, with the rise in recorded new cases despite following the strictest zero-COVID p...

India flags concern as rich nations want to extend mitigation to agriculture

India flags concern as rich nations want to extend mitigation to agriculture

By Nikita Chaurasia

During the ongoing COP27 (UN climate summit) in Egypt, India has countered the developed world’s effort for extending the scope of mitigation to agriculture, stating that rich nations are not seeking to mitigate emissions by modifying their lif...